The tweet was deleted by the author.
But we saved everything 🙂.
PDS Biotechnology announced it will host a virtual key opinion leader (KOL) event on October 15 at 8 a.m. ET. The event will feature Dr. Jonathan M. Hernandez of the U.S. National Cancer Institute, who will join company management to discuss phase 2 clinical outcomes for PDS0301 in advanced liver-associated cancers, with a focus on metastatic colorectal cancer (mCRC).
This session aims to provide an update on the progress of PDS Biotechnology's ongoing research and development in cancer therapeutics.
View post on X Loading...
PDS Biotechnology recently published Phase 2 trial results for its HPV16 immunotherapy and announced a shift in focus to PDS0301 in metastatic colorectal cancer (mCRC). The company is continuing its research in cancer therapeutics with ongoing clinical programs. The upcoming KOL event follows these recent milestones in its development strategy.